ADDED
Aggregate market value of voting and non-voting common equity of Medtronic plc held by non-affiliates of the registrant as of October 24, 2025, based on the closing price of $93.67 as reported on the New York Stock Exchange: approximately $ 120.1 billion.
Number of Ordinary Shares outstanding on June 12, 2026: 1,280,045,190 .
Management s Discussion and Analysis of Financial Condition and Results of Operations 31 7A.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 115 9A.
Risks and uncertainties include those discussed in the section entitled Government Regulation within Item 1.
1 Table of Conten ts Consequently, no forward-looking statement may be guaranteed, and actual results may vary materially from those projected in the forward-looking statements.
We intend to take advantage of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our forward-looking statements.
Except as required by applicable law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
We have three reportable segments that primarily develop, manufacture, distribute, and sell device-based medical therapies and services: the Cardiovascular Portfolio, the Neuroscience Portfolio, and the Medical Surgical Portfolio.
In May 2025, the Company announced its intent to separate the Diabetes Business, with the intention to create a new independent, publicly traded company, MiniMed Group, Inc.
REMOVED
Aggregate market value of voting and non-voting common equity of Medtronic plc held by non-affiliates of the registrant as of October 25, 2024, based on the closing price of $90.59 as reported on the New York Stock Exchange: approximately $ 116.2 billion.
Management s Discussion and Analysis of Financial Condition and Results of Operations 29 7A.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 106 9A.
One must carefully consider forward-looking statements and understand that such forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and involve a variety of risks and uncertainties, known and unknown, including, among others, those discussed in the sections entitled Government Regulation within Item 1.
Consequently, no forward-looking statement may be guaranteed, and actual results may vary materially from those projected in the forward-looking statements.
We intend to take advantage of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our forward-looking statements and are including this sentence for the express purpose of enabling us to use the protections of the safe harbor with respect to all forward-looking statements.
While we may elect to update these forward-looking statements at some point in the future, whether as a result of any new information, future events, or otherwise, we have no current intention of doing so except to the extent required by applicable law.
We have four reportable segments that primarily develop, manufacture, distribute, and sell device-based medical therapies and services: the Cardiovascular Portfolio, the Neuroscience Portfolio, the Medical Surgical Portfolio, and the Diabetes Operating Unit.
For more information regarding our segments, please see Note 19 to the consolidated financial statements in "Item 8.
The portfolio includes the Arctic Front Advanced Cardiac Cryoblation System, PulseSelect single shot Pulsed Field Ablation catheter, the Sphere-9 focal catheter, providing high density mapping capabilities combined with dual radio frequency and pulsed field energies to deliver ablation lesions, and Affera Mapping and Navigation System with Prism-1 software aimed at integrating clinical information to improve patient outcomes.